Related Experiment Video
Updated: Jun 8, 2026
05:17
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
[Molecular targeted therapy in lung cancer]
Koichi Azuma1, Kazuhiko Nakagawa
1Department of Medical Oncology, Kinki University School of Medicine.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|October 20, 2010
Summary
Nonsmall cell lung cancer (NSCLC) treatment has seen progress with molecular-targeting drugs. Therapies like EGFR-TKI, anti-angiogenesis drugs, and EML4-ALK inhibitors offer improved efficacy for NSCLC patients.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Lung cancer remains a leading global cause of cancer mortality.
- Nonsmall cell lung cancer (NSCLC) is the predominant histological subtype.
- Current platinum-based chemotherapy offers limited survival benefits for NSCLC patients.
Purpose of the Study:
- To review the development and impact of molecular-targeting drugs in NSCLC treatment.
- To highlight advancements beyond traditional chemotherapy.
- To discuss specific targeted therapies including EGFR-TKIs, anti-angiogenic agents, and ALK inhibitors.
Main Methods:
- Literature review of clinical trials and research publications.
- Analysis of therapeutic strategies for NSCLC.
- Focus on targeted therapies based on molecular targets.
Main Results:
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKIs) like gefitinib and erlotinib have improved NSCLC therapy efficacy.
- Anti-angiogenetic drugs, such as bevacizumab, are clinically utilized for NSCLC.
- The discovery of EML4-ALK fusions has led to targeted therapies, marking significant progress.
Conclusions:
- Molecular-targeting drugs represent a paradigm shift in NSCLC treatment.
- Targeted therapies offer improved outcomes compared to conventional chemotherapy.
- Continued research into molecular targets is crucial for advancing NSCLC care.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...